Hepatologist Dr. Cyriac Abby Philips, widely known as ‘TheLiverDoc’ on social media, has launched a scathing critique of the new wearable health device, ‘Temple,’ developed by Zomato founder Deepinder Goyal. The device, which carries a price tag of ₹85,000, has become the subject of intense debate after medical professionals raised concerns regarding its ability to monitor physiological metrics such as cerebral blood flow and ‘entropy.’
Temple is described as a pill-shaped sensor intended to be worn on the side of the head near the temple. According to promotional materials released by the company, the device aims to provide continuous monitoring of brain hemodynamics and performance. Deepinder Goyal, who also founded Eternal, announced that pre-orders for the initial batch of the devices commenced on November 1.
The criticism from Dr. Philips centers on the scientific methodology employed by the developers. He argued that the claims regarding the device’s capability to measure brain-related data are unproven and potentially misleading to consumers. In a post on the platform X, Dr. Philips labeled the device a “scam” and dismissed Goyal’s explanations as a “word salad,” asserting that there is no empirical evidence provided to substantiate the device's purported ability to interpret blood flow from a superficial artery.
Dr. Philips further contended that the device is incapable of monitoring brain health, suggesting its function is limited to measuring surface-level blood flow and flushing in the skin. He accused the development team of engaging in “bad science,” “fringe science,” and “statistical misrepresentation.” He drew comparisons to other established health wearables, arguing that those products are validated within the known limits of human physiology, whereas Temple allegedly oversteps these boundaries.
In response to the mounting criticism from the medical community, Deepinder Goyal addressed the controversy in a seven-point statement posted on X. He clarified that Temple is marketed as a fitness and wellness tracker rather than a clinical medical device, thereby placing it outside the typical purview of doctors. He argued that if the device were a scam, it would fail quickly in the market, adding that the company offers a 14-day, no-questions-asked return policy.
Goyal emphasized that the venture is not driven by financial gain, noting that he has personally invested $20 million of his own capital into the project out of a total expenditure of $30 million. He stated that his primary motivation is to advance the science behind the product, and he is not looking to make a quick profit. He also mentioned that the team is working on peer-reviewed publications to follow their existing pre-print papers.
The debate highlights the growing tension between the rapidly evolving wellness wearable industry and established medical skepticism. As Goyal continues to defend the product’s mission, Dr. Philips maintains that the fundamental claims regarding the device’s technical objectives remain unsupported by clear, verifiable data. The company has announced that the device will be made available in six different colours, as it prepares for further public validation of its technology.
Comments